Request Trial
money_istock-504240346_jansucko
jansucko / iStockphoto.com
28 September 2018

CRISPR specialist raises $80m in funding

US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Masimo keeps $634m smartwatch award and moves to appeal
21 July 2026   Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.
Biotech
Arbutus takes Comirnaty LNP patent fight to Canada and UPC
20 July 2026   The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026   Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture.


Editor's picks

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

Editor's picks

Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

More features

Masimo keeps $634m smartwatch award and moves to appeal
Arbutus takes Comirnaty LNP patent fight to Canada and UPC
Why is 2026 already a record year for M&A activity?
Illumina ordered to recall products after German patent ruling
Goodwin launches San Diego office with senior life sciences hire
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
UK-Switzerland strike trade deal with first-of-its-kind pharma rules
IP Federation elects Philips licensing leader as new president